| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E136866-50mg |
50mg |
期货  |
|
| 别名 | 依那普利拉 |
|---|---|
| 英文别名 | AB00698268_09 | Enalaprilat,(S) | L-PROLINE, 1-(N-(1-CARBOXY-3-PHENYLPROPYL)-L-ALANYL)-, (S)- | NCGC00164593-02 | DTXSID0048975 | Q508Q118JM | SCHEMBL37289 | 2-(Ethylamino)-4-(isopropylamino)-6-(methylthio)-s-triazine | MFCD00865786 | Tox21_113430 | Enala |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Enalaprilat |
| 运输条件 | 常规运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 血管紧张素转换酶抑制剂 |
| 产品介绍 |
Enalaprilat is the active form of Enalapril. Enalapril is a ACE (angiotensin-converting enzyme) inhibitor, sμggested to be more potent than Captopril. Studies indicate that Enalapril downregulates the expression of IL-β, IL-6, and NF-κB. Further studies show that Enalapril upregulates the expression of VEGF and heme oxygenase-1. Enalaprilat reports demonstrate that the compound has some antioxidant activity, which does not include the PKC-NADPH oxidase pathway.An active metabolite of Enalapril. Enalaprilat is the active form of Enalapril. Enalapril is a ACE (angiotensin-converting enzyme) inhibitor, suggested to be more potent than Captopril. Studies indicate that Enalapril downregulates the expression of IL-β, IL-6, and NF-κB. Further studies show that Enalapril upregulates the expression of VEGF and heme oxygenase-1. Enalaprilat reports demonstrate that the compound has some antioxidant activity, which does not include the PKC-NADPH oxidase pathway. |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| EC号 | 278-459-3 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid |
| INCHI | 1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1 |
| InChi Key | LZFZMUMEGBBDTC-QEJZJMRPSA-N |
| Smiles | CC(C(=O)N1CCCC1C(=O)O)NC(CCC2=CC=CC=C2)C(=O)O |
| Isomeric SMILES | C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O |
| 关联CAS | 76420-72-9,84680-54-6,84680-54-6 (Parent) |
| NSC Number | 760053 |
| MeSH Entry Terms | 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate;Enalaprilat;Enalaprilat Anhydrous;Enalaprilat Citrate, Anhydrous;Enalaprilat Dihydrate;Enalaprilat, (R)-Isomer, Anhydrous;Enalaprilic Acid;MK 422;MK-422;MK422;Pres iv;Vasotec;Xanef |
| 分子量 | 384.42 |
| Reaxy-Rn | 3656855 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=3656855&ln= |
| 溶解性 | Slightly soluble in water. |
|---|---|
| 分子量 | 348.400 g/mol |
| XLogP3 | -0.700 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 8 |
| 精确质量Exact Mass | 348.169 Da |
| 单同位素质量Monoisotopic Mass | 348.169 Da |
| 拓扑极表面积Topological Polar Surface Area | 107.000 Ų |
| 重原子数Heavy Atom Count | 25 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 490.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 3 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时，请勿进食、饮水或吸烟。 P330: 漱口 P301+P312: 如误吞咽：如感觉不适，呼叫急救中心/医生。 P501: 将内容物/容器处理到。。。 |
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
 I1524076 |
分析证书 | E136866 |
| 1. Zhonghua Dong, Yueyue Sun, Guangwei Wei, Siying Li, Zhongxi Zhao. (2019) A Nucleoside/Nucleobase-Rich Extract from Cordyceps Sinensis Inhibits the Epithelial–Mesenchymal Transition and Protects against Renal Fibrosis in Diabetic Nephropathy. MOLECULES, 24 (22): (4119). [PMID:31739543] [10.3390/molecules24224119] |
首页
400-620-6333
1篇引用文献 
